Biocon Biologics gets EU nod for bone disease treatments, including Osteoporosis, giant cell tumour of bone Ruchika Sharma3 July 2025 11:29 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced that the...
Biocon Biologics Expands Insulin Access in Malaysia Kajal Rajput30 Jun 2025 2:57 PM ISTBiocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of 100 million cartridges of...
Biocon Biologics Yesafili gets Health Canada nod for eye diseases Ruchika Sharma27 Jun 2025 11:36 AM ISTYESAFILI is the first biosimilar to EYLEA to be approved by Health Canada.
Biocon Gets CDSCO Panel Nod to Market Trastuzumab PGS in India Dr. Divya Colin25 Jun 2025 4:51 PM ISTNew Delhi: The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control Organisation (CDSCO),...
Biocon, NCSM partner to launch oncology support program Ruchika Sharma24 Jun 2025 10:15 AM ISTThis collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility, affordability in...
Biocon arm gets marketing nod in UK for plaque psoriasis drug Yesintek Ruchika Sharma26 May 2025 11:37 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has...
Malaysia extends Insulins supply contract with Biocon Biologics arm, Duopharma Marketing for additional 6 months Ruchika Sharma22 May 2025 11:30 AM ISTBengaluru: Biocon Biologics Limited has announced that the Government of Malaysia has agreed to extend the current contract period of 36 months...
Biocon Biologics commercial partner launches psoriatic arthritis injection in Japan Ruchika Sharma21 May 2025 12:29 PM ISTUstekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis.
Biocon Biologics secures multiple market access agreements in US for Yesintek Ruchika Sharma5 May 2025 12:50 PM ISTYESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.
Biocon Biologics receives EMA Committee positive opinions for Biosimilar Denosumab for bone health Ruchika Sharma26 April 2025 12:36 PM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced that the Committee...
Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US Ruchika Sharma15 April 2025 4:18 PM ISTAdditionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1,...
Biocon Biologics gets USFDA nod for cancer drug Jobevne Ruchika Sharma10 April 2025 12:39 PM ISTBengaluru: Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced that the U.S. Food and Drug Administration (U.S. FDA) has...
